Viking Therapeutics, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: San Diego CA United States (2012)

Organization Overview

First Clinical Trial
2015
NCT02578095
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Viking Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

lgd-4033 (1 trial)

vk2809 (2 trials)

Drugs in Phase 1 Trials (1)

vk-0214 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fatty Liver (Phase 2)

Fractures, Bone (Phase 2)

Hip Fractures (Phase 2)

Hypercholesterolemia (Phase 2)

Hyperlipidemias (Phase 2)

Liver Diseases (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 3